Milind Javle

@JavleMilind

Hubert L and Olive Stringer Professor GI Medical Oncology and Attending Physician, MD Anderson Cancer Center
Chair, NCI Task Force Hepatobiliary Cancers

Houston, TX Joined February 2021

390 Following 2K Followers 1K Posts

Latest posts 5

Milind Javle @JavleMilind Oct 24

COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… @curecc @MDAndersonnews

ascopubs.org COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as... PurposePatients with previously treated biliary tract cancer (BTC) have a short median overall survival (OS), and few treatment options. Tovecimig, a bispecific antibody to delta-like ligand-4 and...

Milind Javle @JavleMilind Sep 10

cnn.com/2026/08/19/hea…

www.cnn.com How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages | CNN Patients and researchers point to evidence that many cancer drug dosages are excessive, and that reducing the amount and frequency could save billions of dollars and prevent some of the worst side...

Milind Javle @JavleMilind Aug 28

nytimes.com/2026/08/28/opi…
@DalrympleWill: Rare combination: a historian who can actually write beautifully!

www.nytimes.com Opinion | What It Took to Dismantle the Most Powerful Company in the World A playbook to curb the growing power of Big Tech.

Milind Javle @JavleMilind Aug 28

Proteogenomic profiling identifies FGFR2b as a prevalent cell-surface target in intrahepatic cholangiocarcinoma aacrjournals.org/clincancerres/… Great work by @Nakul2234 @ShuklaSachet for a novel target in cholangiocarcinoma @curecc @ENS_CCA @CrainesCrew @JaruratCare

aacrjournals.org Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic... AbstractPurpose:. Intrahepatic cholangiocarcinoma (iCCA) is increasing in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently,...

Milind Javle @JavleMilind Aug 26

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

smmttx.com/news/press-rel…

smmttx.com Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit... HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy First Phase III Ivonescimab Readout beyond...